These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 18785896)

  • 41. Tolterodine extended-release for overactive bladder.
    Chung DE; Te AE
    Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Flexible dose fesoterodine in the treatment of overactive bladder (OAB).
    Tubaro A; De Nunzio C
    BJU Int; 2013 Aug; 112(3):281-2. PubMed ID: 23826839
    [No Abstract]   [Full Text] [Related]  

  • 43. Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin.
    Jumadilova Z; Varadharajan S; Girase P; Ollendorf DA
    Am J Health Syst Pharm; 2006 Dec; 63(23):2357-64. PubMed ID: 17106009
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of fesoterodine in women with overactive bladder.
    Sand PK; Morrow JD; Bavendam T; Creanga DL; Nitti VW
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Jul; 20(7):827-35. PubMed ID: 19495545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
    Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolterodine for the treatment of overactive bladder: a review.
    Rovner ES
    Expert Opin Pharmacother; 2005 Apr; 6(4):653-66. PubMed ID: 15934891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
    Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH
    J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
    Varadharajan S; Jumadilova Z; Girase P; Ollendorf DA
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S140-9. PubMed ID: 16161387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hallucinations with tolterodine.
    Williams SG; Staudenmeier J
    Psychiatr Serv; 2004 Nov; 55(11):1318-9. PubMed ID: 15534031
    [No Abstract]   [Full Text] [Related]  

  • 51. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of tolterodine in women with detrusor overactivity and anterior vaginal wall prolapse: is it the same?
    Salvatore S; Serati M; Ghezzi F; Uccella S; Cromi A; Bolis P
    BJOG; 2007 Nov; 114(11):1436-8. PubMed ID: 17877779
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
    Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
    J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
    Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z
    BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial.
    Kaplan SA; Schneider T; Foote JE; Guan Z; Carlsson M; Gong J
    BJU Int; 2011 May; 107(9):1432-40. PubMed ID: 20860717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fesoterodine fumarate.
    Gomelsky A; Dmochowski RR
    Drugs Today (Barc); 2010 Feb; 46(2):81-90. PubMed ID: 20393636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [More quality of life again with tolterodine].
    Praxis (Bern 1994); 2006 Oct; 95(42):1636. PubMed ID: 17111848
    [No Abstract]   [Full Text] [Related]  

  • 59. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder.
    Abrams P
    Expert Opin Pharmacother; 2001 Oct; 2(10):1685-701. PubMed ID: 11825311
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.
    Bunyavejchevin S
    J Med Assoc Thai; 2005 Nov; 88(11):1497-501. PubMed ID: 16471092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.